Cardiac Migration of Endogenous Mesenchymal Stromal Cells in Patients with Inflammatory Cardiomyopathy
Table 1
Patients’ baseline characteristics.
Parameter
Total population
No cardiac inflammation
Cardiac inflammation
Significance
29
6
23
Age (years)
48 ± 16
48 ± 15
51 ± 14
n.s.
Male gender
16 (55%)
4 (67%)
12 (52%)
n.s.
NYHA class
4/14/8/2
1/4/1/0
3/10/7/2
n.s.
(I/II/III/IV), in %
(14/48/27/7)
(17/67/17/0)
(13/44/30/9)
Duration of symptoms (month)
3.6 ± 2.4
3.5 ± 3.2
3.7 ± 2.3
n.s.
Cardiac risk factors
Smoking
8 (28%)
3 (50%)
4 (17%)
n.s.
Diabetes mellitus
1 (3%)
0
1 (4%)
n.s.
Hypercholesterinaemia
11 (38%)
1 (17%)
10 (44%)
n.s
Arterial hypertension
16 (55%)
4 (67%)
12 (52%)
n.s.
Medication
ACE-inhibitors/AT1-blocker
16 (55%)
4 (67%)
10 (44%)
n.s.
β-blocker
19 (66%)
3 (50%)
13 (57%)
n.s.
Statins
6 (21%)
1 (17%)
4 (17%)
n.s.
Haemodynamic and echocardiographic measurements
LVEF (%)
52 ± 16
58 ± 22
49 ± 15
0.16
LVEDD (mm)
55.3 ± 8.1
51.6 ± 6.13
59.78 ± 11
0.04
Laboratory parameters
Leukocyte count (/nl)
7.3 ± 2.3
6.4 ± 1.6
7.3 ± 1.9
n.s.
Hs-CRP (mg/dl)
1.9 ± 5.2
1.2 ± 1.8
2.1 ± 6.1
n.s.
NT-proBNP (pg/ml)
949 ± 1901
890 ± 949
1089 ± 2097
n.s.
Endomyocardial biopsy
CD3 (/mm2)
18.8 ± 55.6
4 ± 2
23 ± 61
0.04
LFA-1 (/mm2)
27.5 ± 56.6
7 ± 2
33 ± 63
n.a.
HLA (AF%)
8.9 ± 5.0
7 ± 2
9 ± 6
n.s.
NYHA: dyspnoea according to the New York Heart Association; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end diastolic diameter; hs-CRP: high sensitivity C-reactive protein; CD3: T-lymphocytes; LFA: lymphocyte function-associated antigen-1, CD11a; HLA: human leukocyte antigen; AF: area fraction. Significant values are given for subgroup analyses.
